Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 11/20 | 0.38 |
| ▸ | NMT2 | O60551 | 10/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760195 | 0.93 | EPHX1 (0.42) | EPHX1HDAC1NMT1NMT2EPHX2 | |
| SCHEMBL18786235 | 0.92 | EPHX1 (0.40) | EPHX1HDAC1NMT1NMT2EPHX2 | |
| SCHEMBL18760191 | 0.89 | NMT1 (0.44) | EPHX1NMT1NMT2 | |
| SCHEMBL23840117 | 0.86 | NMT1 (0.40) | EPHX1NMT1NMT2OPRM1OPRD1 | |
| SCHEMBL22223406 | 0.82 | QRFPR (0.41) | HDAC1NMT1NMT2OPRM1OPRD1 | |
| SCHEMBL18785521 | 0.81 | NMT1 (0.37) | NMT1NMT2OPRM1OPRD1 | |
| SCHEMBL20634648 | 0.78 | NMT1 (0.42) | NMT1NMT2EPHX2SMN1; SMN2 | |
| SCHEMBL23840130 | 0.78 | NMT1 (0.42) | NMT1NMT2EPHX2SMN1; SMN2 | |
| SCHEMBL18785522 | 0.78 | NMT1 (0.39) | NMT1NMT2 | |
| SCHEMBL20633489 | 0.77 | NMT1 (0.41) | NMT1NMT2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529424-B2 | Synthetic bioconjugates | SYMIC HOLDINGS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200222548-A1 | SYNTHETIC BIOCONJUGATES | SYMIC HOLDINGS, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529424-B2 | Synthetic bioconjugates | COL14A1, COL1A1, COL2A1 | EPHX1 3596/4885HDAC1 2948/4885NMT1 315/4885 |
| US-20200222548-A1 | SYNTHETIC BIOCONJUGATES | COL14A1, COL1A1, COL2A1 | EPHX1 3596/4885HDAC1 2948/4885NMT1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.